🇪🇺September 9, 2026·Sep 9Research

Phase I Evaluation of Siltartoxatug, a First‐in‐Class Anti‐Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations

Publisher

Europe PMC

This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher: Europe PMC
Region: EU
Scope: Research
Published: September 9, 2026
Language: EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.

Source route

Continue on europepmc.org

Leave the platform to read the original full article on the publisher site.

Source: Europe PMC

Scope: Research

Open original article

Related coverage

More related coverage

Crossref/16h ago

Evaluating the Clinical Use of Cefoperazone/ Sulbactam and Post-discharge Antibiotics Practices in Infectious Diseases Patients

Crossref/16h ago

Polycystic Ovary Syndrome (PCOS) -Associated Infertility: Clinical Insights and Emerging Deep Learning Approaches for Early Detection and Prediction

Crossref/16h ago

Low-Dose Silodosin for Premature Ejaculation: A Clinical Evaluation

Crossref/16h ago

Sociodemographic and Clinical Characteristics of TuberculosisPositivity and Rifampicin Resistance among Presumptive Patients inSouthern Punjab, Pakistan: A Cross-Sectional Study